Exploring Lipid-Based Formulations and Oral Biologics at AAPS PharmSci 360
AAPS PharmSci 360: Innovations in Lipid-Based Formulations
During AAPS PharmSci 360, Pharmaceutical Technology® connected with Karunakar Sukuru, RPh, PhD, the global vice president of Rx Product Development at Catalent Pharma Solutions, to discuss the advantages and challenges associated with lipid-based formulations (LBFs).
The Role of Lipid-Based Drug Delivery Systems
Lipid-based drug delivery systems are experiencing increased demand as 70% of the nearly 8,500 molecules in development feature poor bioavailability. Sukuru emphasized that LBFs can enhance bioavailability even when the molecule lacks aqueous solubility.
Challenges in Oral Delivery of Biologics
- High molecular weight proteins, like monoclonal antibodies, face absorption challenges due to size limitations.
- Sukuru mentioned ongoing efforts to develop novel formulations that open tight junctions, facilitating molecule absorption.
- There are significant hurdles in stabilizing biologic molecules post-delivery to the intestine to prevent destruction in acidic conditions.
Attendees can visit Catalent at Booth #1141 during AAPS PharmSci 360, taking place from October 20-23, 2024, in Salt Lake City, Utah.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.